| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Tourmaline Bio Inc. | TOUR006 - (spiriTED) | Thyroid Eye Disease (TED) | Phase 2b | Ongoing | Intravenous | Opthalmic |
| Tourmaline Bio Inc. | FCR001 - (FREEDOM-2) | Delayed tolerance kidney transplant | Phase 2 | Trial Discontinued | Intravenous | Immunosuppressant |
| Tourmaline Bio Inc. | FCR001 | COVID-19 in living donor kidney transplant (LDKT) patients | Phase 2 | Ongoing | Intravenous | COVID-19 |
| Tourmaline Bio Inc. | FCR001 - (FREEDOM-3) | Scleroderma | Phase 2 | Clinical Pause | Intravenous | Immunology |
| TRACON Pharmaceuticals Inc. | TRC102 in combination with chemoradiation - (NCI trial) | Granulosa cell ovarian cancer | Phase 2 | Ongoing | Oral | Oncology |
| TRACON Pharmaceuticals Inc. | TRC102 | Mesothelioma cancer | Phase 2 | Trial Completed | Intravenous | Oncology |
| TRACON Pharmaceuticals Inc. | DE-122 and Lucentis - AVANTE | Wet age-related macular degeneration (Wet-AMD) | Phase 2 | Trial Discontinued | Intravitreal injection | Opthalmic |
| Tradr 2X Long SNPS Daily ETF | Bryostatin-1 | Alzheimer's disease | Phase 2b | Intravenous | Neurology |